HomeCompareAKYA vs JEPI

AKYA vs JEPI: Dividend Comparison 2026

AKYA yields 155.04% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKYA wins by $29.56M in total portfolio value
10 years
AKYA
AKYA
● Live price
155.04%
Share price
$1.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.59M
Annual income
$13,040,704.30
Full AKYA calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — AKYA vs JEPI

📍 AKYA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKYAJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKYA + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKYA pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKYA
Annual income on $10K today (after 15% tax)
$13,178.29/yr
After 10yr DRIP, annual income (after tax)
$11,084,598.66/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, AKYA beats the other by $11,083,299.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKYA + JEPI for your $10,000?

AKYA: 50%JEPI: 50%
100% JEPI50/50100% AKYA
Portfolio after 10yr
$14.81M
Annual income
$6,521,116.46/yr
Blended yield
44.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AKYA right now

AKYA
Analyst Ratings
2
Buy
7
Hold
Consensus: Hold
Price Target
$4.98
+286.0% upside vs current
Range: $2.40 — $7.50
Altman Z
-4.2
Piotroski
4/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKYA buys
0
JEPI buys
0
No recent congressional trades found for AKYA or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKYAJEPI
Forward yield155.04%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$29.59M$29.0K
Annual income after 10y$13,040,704.30$1,528.62
Total dividends collected$27.44M$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AKYA vs JEPI ($10,000, DRIP)

YearAKYA PortfolioAKYA Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$26,204$15,503.88$11,260$840.19+$14.9KAKYA
2$66,007$37,968.38$12,641$907.94+$53.4KAKYA
3$160,011$89,383.96$14,150$978.20+$145.9KAKYA
4$373,718$202,506.35$15,795$1,050.85+$357.9KAKYA
5$841,906$442,027.47$17,584$1,125.74+$824.3KAKYA
6$1,831,486$930,646.81$19,526$1,202.74+$1.81MAKYA
7$3,851,778$1,892,087.52$21,628$1,281.69+$3.83MAKYA
8$7,840,307$3,718,904.61$23,898$1,362.43+$7.82MAKYA
9$15,463,748$7,074,619.86$26,347$1,444.79+$15.44MAKYA
10$29,586,915$13,040,704.30$28,982$1,528.62+$29.56MAKYA

AKYA vs JEPI: Complete Analysis 2026

AKYAStock

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Full AKYA Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this AKYA vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKYA vs SCHDAKYA vs OAKYA vs KOAKYA vs MAINAKYA vs JEPQAKYA vs XYLDAKYA vs DIVOAKYA vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.